{"schema_version":"secwatch.filing_event.v1","accession":"0001932393-23-000111","form_type":"8-K","ticker":"GEHC","cik":"0001932393","company_name":"GE HealthCare Technologies Inc.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.085716+00:00","generated_at":"2026-06-13T03:24:29.981388+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GE HealthCare Q2 revenues up 9% organically; raises FY2023 guidance","bullets":["Revenue $4.8B, +7% reported, +9% organic; organic orders +6%.","Net income $418M ($0.91 EPS) vs $485M ($1.04) prior year; adjusted EPS $0.92 vs $1.15.","Imaging revenue +9% organic to $2.6B; Pharmaceutical Diagnostics +20% organic to $568M.","FY2023 guidance raised: organic revenue growth 6-8% (prior 5-7%); adjusted EPS $3.70-$3.85 (prior $3.60-$3.75).","Adjusted EBIT margin guidance 15.0%-15.5%, free cash flow conversion 85%+."],"urls":{"canonical":"https://secwatch.observer/filing/0001932393-23-000111","json":"https://secwatch.observer/filing/0001932393-23-000111.json","markdown":"https://secwatch.observer/filing/0001932393-23-000111.md","text":"https://secwatch.observer/filing/0001932393-23-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000111/0001932393-23-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000111/gehc-20230725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:24:29.981388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c06751f007b7dad7a91b695c62d252f40385e2b","claim":"GE HealthCare Technologies Inc. reported second quarter ended June 30, 2023 results: revenue $4.8 billion, net income $418 million, EPS $0.91. Guidance raised.","evidence_excerpt":"raising our top- and bottom-line guidance for the full year as we execute our precision care strategy. ” Second Quarter 2023 Total Company Financial Performance • Revenues of $4.8 billion increased 7% reported and 9% on an Organic basis* year-over-year. Foreign exchange negatively impacted growth by 2%. • Total company orders increased 6% organically, driven by","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000111/0001932393-23-000111-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$4.8 billion"},{"label":"Net income","value":"$418 million"},{"label":"EPS","value":"$0.91"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}